FINANCIAL STATEMENTS (Un-Audited)

For the 1st quarter ended 30th September, 2017

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,

Dhaka-1207, Bangladesh.

AMARSTOCK

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207

As per requirements of the Securitties & Exchange commission's (SEC) Notification No.SEC/CMRRCD/2008-183/Admin/03-34 dated September 27, 2009, The IBN SINA Pharmaceutical Industry Ltd. is pleased to submit the un-audited Statement of Financial Position for the three months period ended 30th September, 2017.

STATEMENT OF FINANCIAL POSITION (Un-Audited)
As at 30th September, 2017

Amount in Taka

	Notes	As at 30.09.2017	As at 30.06.2017
ASSETS:			
Non-Current Assets:		**1,695,528,636**	**1,511,177,231**
Property,Plant and Equipment	02	1,159,584,213	1,116,332,498
Capital work-in-progress		142,395,466	26,614,186
Investment in Marketable Securities (AFS)	03	384,425,810	359,107,400
Investment	03.1	9,123,147	9,123,147
Current Assets :		**674,139,024**	**643,644,663**
Inventories	04	299,221,722	264,194,238
Accounts Receivable		14,857,037	14,642,851
Advances, Deposits & Prepayments	05	183,984,444	167,384,398
Cash & Cash Equivalents	06	176,075,821	197,423,176
TOTAL ASSETS		**2,369,667,660**	**2,154,821,894**
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:		**1,189,513,697**	**1,104,963,231**
Share Capital		258,211,800	258,211,800
Net Gain on Marketable Securities (AFS)	03	312,272,147	289,485,578
Tax Holiday Reserve		4,392,110	4,392,110
Retained Earnings	07	614,637,640	552,873,744
Non-Current Liabilities	08	**364,254,622**	**242,737,392**
Deferred Tax Liability	09	**82,916,155**	**80,513,227**
Current Liabilities:		**732,983,186**	**726,608,044**
Bank Finance	10	249,347,324	326,811,195
Accounts and Other Payables	11	483,635,862	399,796,849
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**2,369,667,660**	**2,154,821,894**
Net Asset Value (NAV) per share		**46.07**	**42.79**

Chief Financial Officer | **Company Secretary** | **Director**

Dated, Dhaka
November 12, 2017

Managing Director | **Chairman**

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)
For the 1st quarter ended 30th September, 2017

	Notes	Amount in Taka	
		From 1st Jul'17 to 30th Sept'17	From 1st Jul'16 to 30th Sept'16
Revenue		1,235,411,188	932,747,415
Cost of goods sold	12	(733,815,468)	(555,308,853)
Gross Profit		**501,595,720**	**377,438,562**
Operating Expenses:			
Administrative expenses	13	(29,137,124)	(23,015,924)
Selling & Distribution expenses	14	(379,464,755)	(292,956,780)
		(408,601,879)	(315,972,704)
Operating Profit		**92,993,841**	**61,465,858**
Finance Charges		(7,509,749)	(2,096,163)
		85,484,092	**59,369,695**
Other Income		50,151	323,370
		85,534,243	**59,693,065**
Workers' P.P. Fund & Welfare Fund		(4,276,712)	(2,842,527)
Net Profit before tax		**81,257,531**	**56,850,538**
Income tax expenses			
Current tax		(19,622,547)	(13,500,252)
Deferred tax	09	128,912	(214,277)
		(19,493,635)	(13,714,529)
Net Profit after tax		**61,763,896**	**43,136,009**
Other Comprehensive Income:			
Change in fair value of Marketable Securities (AFS)	03	25,318,410	19,841,249
Deferred tax		(2,531,841)	(1,984,125)
Total other comprehensive income for the period, net of tax		22,786,569	17,857,124
Total other comprehensive income for the period		**84,550,465**	**60,993,133**
Earnings per share-basic (Adjusted EPS of 2016)		**2.39**	**1.67**

Chief Financial Officer | **Company Secretary** | **Director**

Managing Director | **Chairman**

Dated, Dhaka
November 12, 2017

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CHANGES IN EQUITY (Un-Audited)
For the 1st quarter ended 30th September, 2017

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (unreatized)	Retained Earnings	Total
Balance as at 1st July, 2016	**224,532,000**	**4,392,110**	**259,716,820**	**380,790,698**	**869,431,628**
Statement of profit or loss and other comprehensive Income			29,768,758	233,829,346	263,598,104
Dividend for the year 30 June, 2016 (Cash-12.5%)				(28,066,500)	(28,066,500)
Dividend for the year 30 June, 2016 (Stock-15%)	33,679,800			(33,679,800)	-
Balance as at 1st July, 2017	**258,211,800**	**4,392,110**	**289,485,578**	**552,873,744**	**1,104,963,232**
Statement of profit or loss and other Comprehensive Income for period ended 30th September, 2017			22,786,569	61,763,896	84,550,465
Balance as at 30th September, 2017	**258,211,800**	**4,392,110**	**312,272,147**	**614,637,640**	**1,189,513,697**

STATEMENT OF CHANGES IN EQUITY (Un-Audited)
For the 1st quarter ended 30th September, 2016

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	Gain on Marketable Securities (unreatized)	Retained Earnings	Total
Balance as at 1st January, 2016	**224,532,000**	**4,392,110**	**245,913,549**	**358,108,009**	**832,945,668**
Statement of profit or loss and other		-	13,803,271	78,815,689	92,618,960
Dividend for the year, 2015 (Cash-25%)				(56,133,000)	(56,133,000)
Dividend for the year, 2015 (Stock-10%)					
Balance as at 1st July, 2016	**224,532,000**	**4,392,110**	**259,716,820**	**380,790,698**	**869,431,628**
Statement of profit or loss and other Comprehensive Income for period ended 30th September, 2016			17,857,124	43,136,009	60,993,133
					-
					-
Balance as at 30th September, 2016	**224,532,000**	**4,392,110**	**277,573,944**	**423,926,707**	**930,424,761**

Chief Financial Officer | **Company Secretary** | **Director**

Managing Director | **Chairman**

Dated, Dhaka
November 12, 2017

THE IBN SINA PHARMACEUTICAL INDUSTRY LTD.
STATEMENT OF CASH FLOWS (Un-Audited)
For the 1st quarter ended 30th September, 2017

	Amount in Taka	
	From 1st Jul'17 to 30th Sept'17	**From 1st Jul'16 to 30th Sept'16**
Cash Flow From Operating Activities:		
Collection from customers & others	1,235,146,851	931,209,859
Payment for cost & expenses	(1,089,747,616)	(895,307,764)
Income tax paid	(9,666,764)	(10,340,760)
Financial charges	(7,509,749)	(2,096,163)
Miscellaneous income	50,151	107,529
Net cash flows from operating activities	**128,272,873**	**23,572,701**
Cash Flow From Investing Activities:		
Purchase of fixed assets	(183,057,139)	(23,443,278)
Profit from bank deposits & investment	-	215,841
Net cash used in investing activities	**(183,057,139)**	**(23,227,437)**
Cash Flow From Financing Activities:		
Dividend received/(paid)	(507,043)	(26,605,903)
Long term finance received/(paid) from bank (net)	111,407,826	(13,688,537)
Short term finance received/(paid) from bank (net)	(77,463,872)	57,397,733
Net cash flow from financing activities	**33,436,911**	**17,103,293**
Increase/(decrease) in cash and cash equivalents	(21,347,355)	17,448,557
Cash and cash equivalents at the opening	197,423,176	163,598,844
Cash and cash equivalents at the closing	**176,075,821**	**181,047,401**
Net Operating cash flow per share (NOCFPS) (restated-2016)	**4.97**	**0.91**

Chief Financial Officer **Company Secretary** **Director**

Managing Director **Chairman**

Dated, Dhaka
November 12, 2017

The Ibn Sina Pharmaceutical Industry Ltd.
Selected Notes to the Financial Statements (Un-audited)
For the period ended 30th September, 2017

Selected Explanatory Notes:

01. (a) Basis of Preparation of Financial Statements:

These financial Statements have been prepared in line with the accounting policies and methods of computations of the periodic financial statements prepared and published for the year ended 30th June 2017. These interim financial statements includes only selected explanatory notes as deemed appropriate for understanding of these un-audited financial statements.

01. (b) Reporting:

This 1st quarterly fianacial report has been prepared based on Bangladesh Accounting Statement (BAS)-34 "Interim Financial Reporting".

01. (c) Earnings Per Share (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended September 30, 2017 and profit for the same period. The number of shares outstanding for the period was 25.821 million. Earnings per share for the corresponding period of 2016 has also been calculated based on 25.821 million shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

01. (d) Subsequent events:

No Material events occured after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

01.(e) Finance charge:

Long term loan balance was Tk.375,695,854.00 and 230,663,857.00 on 30 September 2017 and 30 September 2016 respectively. Due to increase in long term loan finance charge was increase during the reporting period.

01.(f) Dividend:

25% Intirm dividend was declared and paid for the period from 1st January 2015 to 31st December 2015 due to change in financial year as per requirement of Finance Act 2016. That is why dividend payment during the period from 1st July 2016 to 30th September 2016 was more than dividend payment during the peroid from 1st July 2017 to 30th September 2017.

01.(g) Net Operating cash flow per share (NOCFPS):

The increase in NOCFPS arrose due to the decrease in percentange of payment for trade and other payable in the current reporting period.

Previous period figures have been re-arranged to conform to current period's presentation, where considered necessary.

	Amount in Taka	
	As at 30.09.2017	**As at 30.06.2017**
02. PROPERTY, PLAND AND EQUIPMENT		
Cost/Revaluation		
Balance as at 1st January	1,606,348,997	1,352,403,379
Addition during the period/year	67,275,859	257,621,978
Disposal/Adjustment during the period/ year	-	(3,676,360)
	1,673,624,856	1,606,348,996
Accumulated Depreciation		
Balance as at 1st January	490,016,499	400,679,809
Charged during the period/year	24,024,144	92,504,197
Disposal/Adjustment during the period/ year	-	(3,167,508)
	514,040,643	490,016,498
Written Down Value (WDV)	**1,159,584,213**	**1,116,332,498**
02.1 Capital work-in-progress		
Construction work-in-progress (Building)	30,851,066	26,614,186
Machinery in transit	111,544,400	-
	142,395,466	**26,614,186**

03. INVESTMENT OF MARKETABLE SECURITIES (FAIR VALUE): 30.09.2017

Sl. No.	Name of Company Share/Bond	No. of Share/Bond Held	Face Value Per Share/ Bond	Cost of Holding	Average Cost	Quoted Rate Per Share/Bond as on 30.09.17	Total Market value of Share/Bond as on 30.09.17	Unrealized Gain/(Loss)
1	Islami Bank Bangladesh Ltd. (IBBL)- in shares	11,013,991	10	32,866,758	2.98	34.50	379,982,690	347,115,932
2	Islami Bank Bangladesh Ltd. (IBBL)-in Mudaraba Perpetual Bond (MPB)	4,590	1,000	4,590,000	1,000	968.00	4,443,120	(146,880)
	Total Tk.			**37,456,758**			**384,425,810**	**346,969,052**

	Amount in Taka	
	As at 30.09.2017	As at 30.06.2017
3.a. Net Gain/(Loss) on Marketable Securities (AFS):		
Unrealized Gain/(Loss) Position (Closing)	346,969,052	321,650,642
Defered tax on gain on marketable securities (AFS)	(34,696,905)	(32,165,064)
	312,272,146	**289,485,578**
3.b. Change in fair value of Marketable Securities (AFS):		
Unrealized Gain/(Loss) Position (Closing)	346,969,052	321,650,642
Unrealized Gain/(Loss) Position (Opening)	321,650,642	288,574,244
	25,318,410	**33,076,398**
03.1 INVESTMENT IN ASSOCIATE		
Opening balance	9,123,147	1,750,000
Add: Addition during the year	-	8,000,000
Less: Share of associate profit/(loss)	-	(626,853)
IBN SINA Consumer Products Ltd.	**9,123,147**	**9,123,147**
04. INVENTORIES		
Raw materials	96,350,939	88,563,456
Packing materials	69,745,694	68,253,484
Work-in-process	45,052,125	43,928,563
Finished goods	87,115,229	61,978,640
Physicians' samples	957,735	1,470,095
	299,221,722	**264,194,238**
05. ADVANCES, DEPOSITS & PRE-PAYMENTS :		
This is recoverable in cash or for value to be received and consists of as follows :		
a. Advances against-		
Salary	2,092,076	2,104,138
Expenses/Works	5,054,200	4,964,944
Head office	7,965,000	7,965,000
Sales centre rent	8,610,337	9,036,110
Motor cycles - To employees	6,058,120	5,649,951
Income Tax	132,780,602	123,113,838
Others	243,278.0	247,492
	162,803,613	**153,081,473**
b. Deposits -		
Security money	**15,818,017**	**12,727,278**
c. Pre-payments -		
Value Added Tax (VAT)	4,796,273	1,009,106
Insurance premium	566,541	566,541
	5,362,814	**1,575,647**
	183,984,444	**167,384,398**

	Amount in Taka	
	As at 30.09.2017	As at 30.06.2017
06. CASH & CASH EQUIVALENTS:		
Cash in hand & Bank Balance	170,393,681	191,833,176
Imprest Cash	5,682,140	5,590,000
	176,075,821	**197,423,176**
07. RETAINED EARNINGS :		
Retained Earnings	552,873,744	319,044,398
Add : Surplus during the period/year	61,763,896	233,829,346
	614,637,640	**552,873,744**
08. NON-CURRENT LIABILITIES:		
Long Term Finance-Net off current maturity	340,903,773	229,495,947
Retirement Benefit Obligations	23,350,849	13,241,445
	364,254,621	**242,737,392**
09. DEFERRED TAX ASSETS/ LIABILITY :		
Deferred tax asset/liability represents deferred tax recognized as asset/liability the movement of which is as below:		
(a) Deferred tax liability on net temprorary differences:		
Balance as at 1st July	48,348,164	39,478,199
Deferred tax expenses/(income)	(128,912)	8,869,965
	48,219,251	**48,348,164**
(b) Deferred tax liability on change in AFS of Financial Assets:		
Balance as at 1st January	32,165,063	28,857,423
Addition/(Less) during the period	2,531,841	3,307,640
	34,696,904	**32,165,063**
Deferred tax liability at March 31st (a+b)	**82,916,155**	**80,513,227**
10 BANK FINANCE:		
Short Term Finance	214,555,242	280,421,753
Long Term Finance-Current maturity	34,792,082	46,389,442
	249,347,324	**326,811,195**
11. ACCOUNTS AND OTHER PAYABLES:		
Payable for Suppliers	166,657,695	141,010,095
Accrued Expenses	108,657,420	85,580,582
Deposits	9,308,916	7,183,446
Other Finance	65,234,100	51,867,542
Income Tax Liability	133,777,731	114,155,184
	483,635,862	**399,796,849**

	Amount in Taka	
	From 1st July'17 to 30th September'17	From 1st July'16 to 30th September'16
12. COST OF GOODS SOLD :		
Materials	592,598,789	452,286,410
Factory Overhead	120,612,806	85,245,265
Depreciation	20,603,873	17,777,178
	733,815,468	**555,308,853**
13. ADMINISTRATIVE EXPENSES :		
Salary, wages & Allowances	16,902,108	14,475,946
Repairs & Maintenance	1,504,455	1,147,415
Travelling & Conveyance	592,613	544,442
AGM, Fees and Others	201,200	372,490
Depreciation	1,290,312	1,270,335
Other Expenses	8,646,436	5,205,296
	29,137,124	**23,015,924**
14. SELLING & DISTRIBUTION EXPENSES :		
Salary, wages & Allowances	213,128,843	158,720,288
Travelling & Conveyance	702,097	624,842
Market Survey & Research and Product development	686,606	472,719
Field personnel expenses	49,082,490	40,532,265
Sample, Literature & Promotional Expenses	32,944,778	22,548,737
Delivery Expenses	35,101,755	32,261,810
Depreciation	2,129,958	2,291,313
Other Expenses	45,688,229	35,504,806
	379,464,755	**292,956,780**

Chief Financial Officer | Company Secretary | Director

Dated, Dhaka
12-Nov-17

Managing Director | Chairman

AMARSTOCK